Glycopyrrolate for End-of-Life Congestion Management

Introduction to Glycopyrrolate

• The National Comprehensive Cancer Network recommends glycopyrrolate for managing respiratory congestion in patients with PPS 20 experiencing end-of-life secretions, with a typical dosage of 0.2-0.4 mg IV every 4 hours as needed or 0.2 mg subcutaneously every 4 hours 1, 2

Understanding PPS 20 and Implications

• A Palliative Performance Scale (PPS) score of 20 indicates end-of-life stage with very limited life expectancy (days to weeks) 3
• A PPS score of 20 is characterized by a completely bed-bound patient, unable to carry out any self-care, with limited oral intake, and often drowsy or reduced level of consciousness 2, 1

Pharmacologic Management of Respiratory Congestion

• The National Comprehensive Cancer Network suggests glycopyrrolate 0.2-0.4 mg IV every 4 hours PRN as a first-line anticholinergic option for managing respiratory congestion in PPS 20 patients 2
• Alternative anticholinergics, such as scopolamine 0.4 mg subcutaneously every 4 hours PRN, may be considered if glycopyrrolate is unavailable 2, 3

Advantages of Glycopyrrolate

• Glycopyrrolate does not cross the blood-brain barrier effectively, making it less likely to cause delirium compared to other anticholinergics 3
• Glycopyrrolate provides effective reduction of respiratory secretions 1

Administration Considerations

• For PPS 20 patients with limited oral intake, parenteral routes (IV, subcutaneous) are preferred 2
• Subcutaneous administration is often most practical in home/hospice settings 3

Monitoring and Expected Outcomes

• Efficacy of glycopyrrolate can be assessed by reduction in audible respiratory secretions and decreased need for suctioning 3, 1
• Improved comfort for the patient is also an expected outcome of glycopyrrolate treatment 1

Comprehensive Approach

• Non-pharmacological measures, such as positioning the patient with head slightly elevated and gentle suctioning if necessary, can be used in conjunction with glycopyrrolate 1, 2
• Providing education to family about natural end-of-life processes is also an important aspect of comprehensive care 2

Additional Considerations

• If respiratory congestion is accompanied by dyspnea, consider adding opioids to the treatment regimen 1, 3
• As life expectancy decreases, the role of anticholinergics like glycopyrrolate increases in importance 3
• Ensure interventions align with goals of care for this end-of-life patient 2

Clinical Pearls

• Start glycopyrrolate early when congestion is first noted rather than waiting until secretions become severe 1
• Anticholinergics are more effective at preventing new secretion formation than eliminating existing secretions 3
• Combining glycopyrrolate with other palliative medications, such as opioids for dyspnea and benzodiazepines for anxiety, may provide more comprehensive symptom management 1, 3